Invesco
LYEL icon

Invesco’s Lyell Immunopharma LYEL Stock Holding History

Invesco’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Buy
+13,914
New +$252K ﹤0.01% 3602
2026
Q1 		– Sell
-98,649
Closed -$3.04M – 3790
2025
Q4 		$3.04M Buy
+98,649
New +$2.21M ﹤0.01% 2447
2025
Q3 		– Sell
-12,809
Closed -$113K – 3829
2025
Q2 		$113K Sell
12,809
-6,135
-32% -$55.9K ﹤0.01% 3636
2025
Q1 		$204K Sell
18,944
-1,416
-7% -$17.3K ﹤0.01% 3506
2024
Q4 		$261K Buy
20,360
+63
+0.3% +$1.25K ﹤0.01% 3457
2024
Q3 		$560K Sell
20,297
-46
-0.2% -$1.35K ﹤0.01% 3186
2024
Q2 		$590K Sell
20,343
-127
-0.6% -$6.05K ﹤0.01% 3207
2024
Q1 		$913K Buy
20,470
+4,915
+32% +$210K ﹤0.01% 3034
2023
Q4 		$604K Buy
15,555
+919
+6% +$33.1K ﹤0.01% 3123
2023
Q3 		$430K Buy
14,636
+103
+0.7% +$4.89K ﹤0.01% 3272
2023
Q2 		$924K Buy
14,533
+74
+0.5% +$4.09K ﹤0.01% 2934
2023
Q1 		$682K Buy
14,459
+11,675
+419% +$624K ﹤0.01% 3103
2022
Q4 		$193K Sell
2,784
-12,766
-82% -$1.27M ﹤0.01% 3693
2022
Q3 		$2.28M Buy
15,550
+12,744
+454% +$1.73M ﹤0.01% 2583
2022
Q2 		$366K Sell
2,806
-128
-4% -$13.1K ﹤0.01% 3488
2022
Q1 		$296K Buy
2,934
+2,357
+408% +$286K ﹤0.01% 3640
2021
Q4 		$89K Buy
+577
New +$129K ﹤0.01% 3917

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Invesco's LYEL Position: Q2 2026 in Review

Invesco opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 13,914 shares worth $195K. The stake represents ﹤0.01% of the portfolio and ranks #3602 among its holdings. This is a return to the name: Invesco previously reported a position in LYEL as recently as Q4 2025.

Invesco first reported a position in LYEL in Q4 2021 and has held it in 17 quarters since. The position peaked at $3.04M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Invesco held 13,914 shares of Lyell Immunopharma worth $195K as of Q2 2026.
  • Lyell Immunopharma was a new Invesco position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3602 holding.
  • Invesco first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 17 quarters since.
  • Invesco's Lyell Immunopharma position peaked at $3.04M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.